WO2020182831A1 - Food supplement - Google Patents
Food supplement Download PDFInfo
- Publication number
- WO2020182831A1 WO2020182831A1 PCT/EP2020/056386 EP2020056386W WO2020182831A1 WO 2020182831 A1 WO2020182831 A1 WO 2020182831A1 EP 2020056386 W EP2020056386 W EP 2020056386W WO 2020182831 A1 WO2020182831 A1 WO 2020182831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food supplement
- maximum
- ingredients
- weight
- supplement according
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 73
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229940063673 spermidine Drugs 0.000 claims abstract description 23
- 239000004615 ingredient Substances 0.000 claims abstract description 22
- ZMJBYMUCKBYSCP-AWFVSMACSA-N (1s,2r)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid Chemical class OC(=O)[C@@H](O)[C@@](O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-AWFVSMACSA-N 0.000 claims abstract description 16
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 11
- GUNURVWAJRRUAV-UHFFFAOYSA-N N(1)-acetylspermine Chemical compound CC(=O)NCCCNCCCCNCCCN GUNURVWAJRRUAV-UHFFFAOYSA-N 0.000 claims abstract description 8
- FONIWJIDLJEJTL-UHFFFAOYSA-N N(8)-acetylspermidine Chemical compound CC(=O)NCCCCNCCCN FONIWJIDLJEJTL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005700 Putrescine Substances 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 8
- 229940063675 spermine Drugs 0.000 claims abstract description 8
- 229940094952 green tea extract Drugs 0.000 claims abstract description 7
- NQNXERHVLXYXRO-UHFFFAOYSA-N Diacetylspermine Chemical compound Cl.Cl.CC(=O)NCCCNCCCCNCCCNC(C)=O NQNXERHVLXYXRO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019197 fats Nutrition 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 16
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 10
- 229940075559 piperine Drugs 0.000 claims description 10
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 10
- 235000019100 piperine Nutrition 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 241000593508 Garcinia Species 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- 229960002173 citrulline Drugs 0.000 claims description 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 5
- 239000006014 omega-3 oil Substances 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 235000021283 resveratrol Nutrition 0.000 claims description 5
- 229940016667 resveratrol Drugs 0.000 claims description 5
- 229960004799 tryptophan Drugs 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 235000021537 Beetroot Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- -1 diacetylspermin Chemical compound 0.000 claims description 3
- 229940087603 grape seed extract Drugs 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 235000009569 green tea Nutrition 0.000 claims description 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 22
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000002775 capsule Substances 0.000 abstract description 8
- 230000037221 weight management Effects 0.000 abstract description 7
- 230000003712 anti-aging effect Effects 0.000 abstract description 5
- 230000004580 weight loss Effects 0.000 abstract description 5
- 235000000885 Garcinia xanthochymus Nutrition 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 2
- 244000119461 Garcinia xanthochymus Species 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 32
- 210000001789 adipocyte Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N (+)-Erythro-hydroxycitric acid Natural products OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229940089491 hydroxycitric acid Drugs 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008450 motivation Effects 0.000 description 5
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013585 weight reducing agent Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 235000013367 dietary fats Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 244000306517 Rheedia brasiliensis Species 0.000 description 1
- 235000004539 Rheedia brasiliensis Nutrition 0.000 description 1
- 244000272739 Vitis cinerea Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the invention relates to a food supplement, for example a fitness shake.
- triglycerides in fat cells can be broken down through exercise.
- the triglycerides in the fat cells only begin to burn after the carbohydrate stores in the body have been burned. This leads to the fact that even with forced sporting activity there is no combustion of the triglycerides in the fat cells for some time.
- physical activity only leads to fat loss if it is carried out persistently and over a longer period of time, usually at least one hour.
- these fat cells remain metabolically dysfunctional, as they form fat deposits more quickly due to the changed, disadvantageous enzyme activity when fat is consumed (yo-yo effect).
- these "old" fat cells which have already changed, show an increased secretory activity of proinflammatory interleukins compared to healthy cells, which can be responsible for negative effects on physiological processes (including diabetes).
- diets i.e. by reducing the supply of energy - as with sporting activity - ultimately mobilizes fat reserves in the body after some time, since there is not enough energy available to maintain physiological activity. Accordingly, the effects of diets are physiologically comparable to the processes in the body described in connection with physical activity.
- Another known method for weight loss is to administer drugs that can bind dietary fats in the intestine, such as ß-1,4-polymer from D-glucosamine and N-acetyl-D-glucosamine and other dietary fiber complexes. Even with this method On the one hand, fat deposits in fat cells are broken down and the new build-up of triglycerides in existing fat cells is inhibited; on the other hand, the old fat cells remain in the body with the disturbed metabolism, which has the negative effects described above.
- drugs that can bind dietary fats in the intestine, such as ß-1,4-polymer from D-glucosamine and N-acetyl-D-glucosamine and other dietary fiber complexes.
- lipase inhibitors such as orlistat
- lipase inhibitors prevent the splitting of dietary fats into smaller lipids, which can only be absorbed by the body in this form.
- these active ingredients specifically and long-lasting inhibition of fat-digesting enzymes (lipases) of the gastrointestinal tract.
- the therapeutic effect begins within the stomach and continues in the area of the upper small intestine. From a chemical point of view, such active substances bind covalently to the active center of gastric and pancreatic lipase (pancreatic lipase).
- these lipases are irreversibly inactivated and can no longer break down (hydrolyze) the dietary fats present in the form of triglycerides into absorbable free fatty acids and monoglycerides.
- the digestion and absorption of up to 35% of the fats ingested with food are prevented, thus lowering serum cholesterol.
- This primarily results in a reduction in body weight, which secondarily improves glucose tolerance and increased blood pressure values can decrease (see metabolic syndrome).
- metabolically disturbed fat cells remain. The so-called yo-yo effect can be expected even after taking lipase inhibitors.
- the object of the present invention is to provide a food supplement, in particular a fitness drink, for increasing fitness through sustainable weight management.
- a food supplement according to the invention for example a fitness shake or a capsule, comprises:
- ingredients from a group of derivatives of citric acid in particular di- or trivalent salts of the (-) - hydroxycitric acid isomer, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract; and
- ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermin, diacetylspermin, and cadaverine one or more of the ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermin, diacetylspermin, and cadaverine.
- the composition comprises, on the one hand, active ingredients and active ingredient complexes to stimulate fat loss.
- active ingredients and active ingredient complexes to stimulate fat loss can be: derivatives of citric acid, in particular the divalent or trivalent salt of the (-) - hydroxycitric acid isomer; Extracts from Garcinia species (for example Garcinia brasiliensis, Garcinia cambogia); polyunsaturated diacylglycerides; Green tea extracts (caffeine, epigallocatechin gallate ...
- the composition comprises biogenic polyamines for the conversion of metabolically diseased into healthy adipocytes, in particular putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine and / or cadaverine.
- HCA hydroxycitric acid
- Active ingredients and active ingredient complexes to stimulate fat breakdown and to inhibit the build-up of fat deposits in the cells, which act as competitive inhibitors of the adenosine triphosphate citrate phase, reduce the cellular availability of acetyl coenzyme A for fatty acid and cholesterol biosynthesis.
- administration of HCA also stimulates beta-oxidation (fipolysis) and reduces food intake.
- the food supplement according to the invention also contains biogenic polyamines (e.g. spermidine, which is mentioned below as representative of this group of active substances) for converting metabolically diseased into healthy adipocytes.
- biogenic polyamines e.g. spermidine, which is mentioned below as representative of this group of active substances
- spermidine which is mentioned below as representative of this group of active substances
- These active ingredients create new metabolically healthy cells that do not show this increased willingness to store fats due to the high enzyme activity (adipogenesis).
- the cells that are already metabolically diseased are converted into metabolically healthy cells by the administration of spermidine and the resulting autophagy.
- spermidine Through the additional administration of the active ingredient spermidine, new metabolically healthy cells are formed which do not show this increased willingness to store fats due to the high enzyme activity (adipogenesis).
- spermidine promotes cell growth and differentiation in the course of adipogenesis.
- spermidine stimulates the autophagy of the cells and thereby breaks down existing old cell structures and proteins, which are replaced by new functional components.
- the cells that are already metabolically diseased are converted into metabolically healthy cells by the administration of spermidine and the resulting autophagy.
- the spermidine contained in the food supplement according to the invention also has the property of inducing the release of anti-inflammatory messenger substances by forming new, metabolically healthy adipocytes, which release anti-inflammatory cytokines which, among other things, regulate the glucose metabolism and thus also promote effective weight management.
- Fat cells with impaired metabolism are converted into metabolically healthy fat cells by stimulating the Adipogenesis and autophagy with simultaneous mobilization of existing fat reserves and inhibition of lipogenesis accelerated.
- a combination of (-) - hydroxycitric acid containing Garcinia extract and spermidine has proven to be particularly suitable for the basic formulation of the food supplement according to the invention.
- the basic formulation with the specified minimum amounts of ingredients ensures the effects according to the invention.
- the additives mentioned below are optionally added in order to meet specific objectives or to achieve additional effects or reinforcements of the effects according to the invention.
- the food supplement comprises: 0.5-80% by weight, in particular 30-70% by weight, of the one or more ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of (-) - hydroxycitric acid Isomers, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract; and
- the dietary supplement preferably contains between 0.25 and 40 g, in particular between 0.15 and 35 g, of the one or more ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of (-) - hydroxycitric acid Isomers, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract, based on a daily dose of the dietary supplement; and or
- the one or more ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine, and cadaverine, based on a Daily dose of the dietary supplement.
- the weight information relates to a recommended daily dose of the dietary supplement to be taken.
- a daily dose for the above is Weight specifications usually 50 g.
- the quantitative data insofar as they are given as weight data, relate to 100 g of the food supplement, that is to say can easily be converted into% by weight.
- the food supplement can advantageously contain 0-0.500% by weight piperine, in particular 0.150-0.350% by weight piperine. Piperine increases the bioavailability of the active ingredients of the food supplement according to the invention and thus enhances the effects of the composition.
- the food supplement can furthermore contain up to a maximum of 10 g fat, in particular 0 to 10% by weight of saturated fatty acids, in particular 0 to 10% by weight of omega-3 fatty acids.
- omega-3 fatty acids By adding omega-3 fatty acids, an increase in moisture and health is achieved.
- the food supplement can optionally contain carbohydrates, but a maximum of 33% by weight of carbohydrates in the form of sugar. Carbohydrates are then optionally added if a long-lasting effect is to be achieved during endurance training and taking the food supplement before exercise.
- the addition of a proportion of sugar e.g. grape sugar
- the dietary supplement can contain a maximum of 93% by weight of protein.
- protein promotes muscle building during strength training.
- amino acids can also be added to the dietary supplement.
- the dietary supplement can contain a maximum of 3.3% by weight beetroot.
- the food supplement can contain a maximum of 266.5 mg of vitamin C, based on a daily dose of the food supplement.
- Vitamin C ensures a further increase in endurance. 100-133 mg of vitamin C are preferred.
- the food supplement can contain up to a maximum of 1.3 g of caffeine, in particular as an extract from green tea, based on 100 g of the food supplement.
- caffeine in particular as an extract from green tea, based on 100 g of the food supplement.
- the consumption of caffeine stimulates fat loss and also leads to an increase in motivation.
- the food supplement can contain a maximum of 5 g resveratrol and / or grape seed extract, based on a daily dose of the food supplement.
- This active ingredient can be added to increase the anti-aging effect.
- the active ingredient acts as an antioxidant.
- Preferably 1.75-3.75 g resveratrol and / or grape seed extract are added.
- the food supplement can preferably contain up to a maximum of 5 g of L-citrulline, based on a daily dose of the food supplement.
- L-citrulline leads on the one hand to an increase in performance and on the other hand reduces the risk or the effects of sore muscles (lowering of the plasma lactate level).
- the dietary supplement preferably contains 1.75-3.75 g of L-citrulline.
- the dietary supplement can contain up to a maximum of 1.65 g L-tryptophan and / or L-tyrosine, based on a daily dose of the dietary supplement. These substances promote the formation of happiness hormones. Taking them leads to an increase in motivation, e.g. to be physically active and thus promotes the effects of the basic recipe. It can preferably contain 0.5-1 g of L-tryptophan and / or L-tyrosine.
- the dietary supplement can contain up to a maximum of 2.3 mg vitamin B6, based on a daily dose of the dietary supplement. Vitamin B6 also promotes the formation of happiness hormones and thus increases motivation.
- the food supplement can contain up to a maximum of 1 g of salt, based on a daily dose of the food supplement.
- the food supplement can also contain chromium (e.g. 0.01-0.1 mg) and / or choline (e.g. 50-1000 mg), based on a daily dose.
- chromium e.g. 0.01-0.1 mg
- choline e.g. 50-1000 mg
- the food supplement can in principle be provided in all possible forms, e.g. as a capsule, as a solution or suspension of the ingredients, as a powder that can be dissolved in water, or as a finished drink (fitness drink).
- a finished drink fittingness drink
- the amounts given for the food supplement according to the invention are given in parts by weight or in absolute weight figures which relate to the finished drink or drink to be prepared as intended.
- an auxiliary or filler e.g. Water, in which the other ingredients or active ingredients according to the invention are dissolved.
- a suspension of water and amino acids for example, is also conceivable as the basis for a drink, in which the other ingredients are dissolved or into which the active ingredients according to the invention are incorporated.
- auxiliaries or fillers are water, hydroxypropylmethylcellulose, amino acids and / or fatty acids.
- the daily dose of necessary or optional ingredients can be mixed with any auxiliaries or fillers in order to provide the food supplement in the desired dosage form.
- any auxiliaries or fillers in order to provide the food supplement in the desired dosage form.
- the following diet supplements in the form of a fitness drink are for weight management purposes.
- the recipe can be adapted by setting the exact amounts of active ingredients and optional additives.
- the following examples correspond to formulations that are effective for certain (additional) objectives.
- auxiliary e.g. water
- auxiliary e.g. water
- auxiliary e.g. water
- auxiliary e.g. water
- auxiliary material e.g. water
- the data relate to 100 mg of the food supplement.
- the daily dose can be, for example, depending on the request and physiological
- the following dietary supplement in capsule form serves weight management purposes.
- the recipe can be adapted by setting the exact amounts of active ingredients and optional additives.
- This example relates to a dosage form as a capsule weighing 1 g.
- the quantities are given below for two 1 g capsules:
- a daily dose corresponds to two (2) capsules.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a food supplement in the form of a fitness drink or capsule comprising: 0.5-80 g of one or more of the ingredients from a group of derivatives of citric acid, more particularly bivalent or trivalent salts of the (-)-hydroxycitric acid isomer, extracts from garcinia varieties, multiply unsaturated diglycerides and green tea extract, in relation to 100 g of the food supplement; and 0.001-20 g of one or more of the ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine, and cadaverine, in relation to 100 g of the food supplement. The food supplement according to the invention can be used to achieve sustainable weight management or sustainable weight loss by fat reduction in the body. Moreover, the administration of the active ingredient composition according to the invention achieves an anti-ageing effect.
Description
TITEL TITLE
Nahrungsergänzungsmittel Food supplements
TECHNISCHES GEBIET TECHNICAL AREA
Die Erfindung betrifft ein Nahrungsergänzungsmittel, beispielsweise einen Fitness-Shake. The invention relates to a food supplement, for example a fitness shake.
STAND DER TECHNIK STATE OF THE ART
Derzeit sind verschiedenste Methoden bekannt, um einerseits den Abbau von Triglyzeriden in den Fettgeweben zu fördern, und andererseits um den Aufbau von Triglyzeriden zu hemmen. A wide variety of methods are currently known to promote the breakdown of triglycerides in adipose tissues on the one hand and to inhibit the build-up of triglycerides on the other.
So können durch sportliche Betätigung grundsätzlich Triglyzeride in Fettzellen abgebaut werden. Allerdings beginnt die Verbrennung der in den Fettzellen befindlichen Triglyzeriden erst nach Verbrennung der im Körper befindlichen Kohlenhydratspeicher. Dies führt dazu, dass auch bei forcierter sportlicher Betätigung für einige Zeit keine Verbrennung der in den Fettzellen befindlichen Triglyzeride stattfindet. Somit führt eine sportliche Betätigung nur dann zu Fettabbau, wenn sie ausdauernd und über einen längeren Zeitraum, meist mindestens eine Stunde, durchgeführt wird. Auch nach Abbau der Triglyzeride in den Fettzellen bleiben diese Fettzellen metabolisch dysfunktional, da sie durch die veränderte nachteilige Enzymaktivität bei Fettzufuhr schneller wieder Fettdepots bilden (Yo-Yo Effekt). Zudem weisen diese bereits veränderten „alten“ Fettzellen gegenüber gesunden Zellen eine erhöhte sekretorische Aktivität von proinflammatorischen Interleukinen auf, welche für negative Auswirkungen auf physiologische Prozesse verantwortlich sein können (u.a. Diabetes). In principle, triglycerides in fat cells can be broken down through exercise. However, the triglycerides in the fat cells only begin to burn after the carbohydrate stores in the body have been burned. This leads to the fact that even with forced sporting activity there is no combustion of the triglycerides in the fat cells for some time. Thus, physical activity only leads to fat loss if it is carried out persistently and over a longer period of time, usually at least one hour. Even after the triglycerides in the fat cells have been broken down, these fat cells remain metabolically dysfunctional, as they form fat deposits more quickly due to the changed, disadvantageous enzyme activity when fat is consumed (yo-yo effect). In addition, these "old" fat cells, which have already changed, show an increased secretory activity of proinflammatory interleukins compared to healthy cells, which can be responsible for negative effects on physiological processes (including diabetes).
Die Durchführung von Diäten, sprich durch die Herabsetzung der Zufuhr von Energie, werden - wie bei sportlicher Betätigung - letztendlich nach einiger Zeit Fettreserven im Körper mobilisiert, da für den Erhalt der physiologischen Aktivität nicht genügend Energie zur Verfügung steht. Dementsprechend sind die Auswirkungen von Diäten physiologisch vergleichbar mit den im Zusammenhang mit der sportlichen Betätigung beschriebenen Prozessen im Körper. The implementation of diets, i.e. by reducing the supply of energy - as with sporting activity - ultimately mobilizes fat reserves in the body after some time, since there is not enough energy available to maintain physiological activity. Accordingly, the effects of diets are physiologically comparable to the processes in the body described in connection with physical activity.
Eine weitere bekannte Methode zur Gewichtsreduktion besteht darin, Wikstoffe zu verabreichen, die Nahrungsfette im Darm binden können, wie zum Beispiel ß-l,4-Polymer aus D-Glucosamin sowie N-Acetyl-D-Glucosamin und andere Ballaststoffkomplexe. Auch bei dieser Methode
werden einerseits Fettdepots in Fettzellen abgebaut als auch der neuerliche Aufbau von Triglyzeriden in bestehenden Fettzellen gehemmt, andererseits verbleiben die alten Fettzellen mit dem gestörten Stoffwechsel im Körper, was die oben beschriebenen negativen Effekte nach sich zieht. Another known method for weight loss is to administer drugs that can bind dietary fats in the intestine, such as ß-1,4-polymer from D-glucosamine and N-acetyl-D-glucosamine and other dietary fiber complexes. Even with this method On the one hand, fat deposits in fat cells are broken down and the new build-up of triglycerides in existing fat cells is inhibited; on the other hand, the old fat cells remain in the body with the disturbed metabolism, which has the negative effects described above.
Eine weitere Möglichkeit zur Gewichtsreduktion besteht in der Verabreichung von Lipase- Inhibitoren (wie z.B. Orlistat). Diese verhindern die Spaltung von Nahrungsfetten in kleinere Lipide, welche nur in dieser Form vom Körper aufgenommen werden können. Somit hemmen diese Wirkstoffe spezifisch und langanhaltend fettverdauende Enzyme (Lipasen) des Magen- Darm-Traktes. Die therapeutische Wirkung beginnt innerhalb des Magens und setzt sich im Bereich des oberen Dünndarms fort. Chemisch gesehen binden solche Wirkstoffe kovalent an das aktive Zentrum der gastrischen und pankreatischen Lipase (Pankreaslipase). Dadurch werden diese Lipasen irreversibel inaktiviert und können die in Form von Triglyceriden vorliegenden Nahrungsfette nicht mehr in resorbierbare freie Fettsäuren und Monoglyceride zerlegen (hydrolysieren). In der Folge werden die Verdauung und die Resorption von bis zu 35 % der mit der Nahrung aufgenommenen Fette verhindert und so das Serumcholesterin gesenkt. Hieraus resultiert primär eine Verringerung des Körpergewichts, wodurch sich sekundär die Glucosetoleranz verbessert und erhöhte Blutdruckwerte sinken können (siehe metabolisches Syndrom). Auch hier bleiben jedoch metabolisch gestörte Fettzellen bestehen. So ist auch nach Einnahme von Lipase Inhibitoren der sogenannte Yo-Yo-Effekt zu erwarten. Another possibility for weight loss is the administration of lipase inhibitors (such as orlistat). These prevent the splitting of dietary fats into smaller lipids, which can only be absorbed by the body in this form. Thus, these active ingredients specifically and long-lasting inhibition of fat-digesting enzymes (lipases) of the gastrointestinal tract. The therapeutic effect begins within the stomach and continues in the area of the upper small intestine. From a chemical point of view, such active substances bind covalently to the active center of gastric and pancreatic lipase (pancreatic lipase). As a result, these lipases are irreversibly inactivated and can no longer break down (hydrolyze) the dietary fats present in the form of triglycerides into absorbable free fatty acids and monoglycerides. As a result, the digestion and absorption of up to 35% of the fats ingested with food are prevented, thus lowering serum cholesterol. This primarily results in a reduction in body weight, which secondarily improves glucose tolerance and increased blood pressure values can decrease (see metabolic syndrome). Here too, however, metabolically disturbed fat cells remain. The so-called yo-yo effect can be expected even after taking lipase inhibitors.
AUFGABE DER ERFINDUNG OBJECT OF THE INVENTION
Ausgehend davon besteht die Aufgabe der vorliegenden Erfindung darin, ein Nahrungsergänzungsmittel, insbesondere ein Fitnessgetränk, zur Steigerung der Fitness durch nachhaltiges Gewichtsmanagement bereitzustellen. Based on this, the object of the present invention is to provide a food supplement, in particular a fitness drink, for increasing fitness through sustainable weight management.
TECHNISCHE LOSUNG TECHNICAL SOLUTION
Diese Aufgabe wird gelöst durch die Bereitstellung eines Nahrungsergänzungsmittels gemäß Anspruch 1. Vorteilhafte Ausführungsformen ergeben sich aus den Merkmalen der abhängigen Ansprüche.
Ein erfindungsgemäßes Nahrungsergänzungsmittel, beispielsweise ein Fitness-Shake oder eine Kapsel, umfasst: This object is achieved by providing a food supplement according to claim 1. Advantageous embodiments emerge from the features of the dependent claims. A food supplement according to the invention, for example a fitness shake or a capsule, comprises:
einen oder mehrere der der Inhaltsstoffe aus einer Gruppe von Derivaten der Zitronensäure, insbesondere zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers, Extrakten aus Garcinia Arten, mehrfach ungesättigten Diacylglyzeriden, und Grünteeextrakt; und one or more of the ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of the (-) - hydroxycitric acid isomer, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract; and
einen oder mehrere der Inhaltsstoffe aus einer Gruppe von Putrescin, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und Cadaverin. one or more of the ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermin, diacetylspermin, and cadaverine.
Die Zusammensetzung umfasst zum einen Wirkstoffe und Wirkstoff-Komplexe zur Stimulierung des Fettabbaus. Diese können sein: Derivate der Zitronensäure, insbesondere das zwei- oder dreiwertige Salz des (-)-Hydroxyzitronensäure-Isomers; Extrakte aus Garcinia Arten (z.B. Garcinia brasiliensis, Garcinia cambogia); mehrfach ungesättigte Diacylglyzeride; Grüntee Extrakte (Koffein, Epigallocatechingallate...
Zum anderen umfasst die Zusammensetzung biogene Polyamine zur Umwandlung von metabolisch kranken in gesunde Adipozyten, insbesondere Putrescine, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und/oder Cadaverin. The composition comprises, on the one hand, active ingredients and active ingredient complexes to stimulate fat loss. These can be: derivatives of citric acid, in particular the divalent or trivalent salt of the (-) - hydroxycitric acid isomer; Extracts from Garcinia species (for example Garcinia brasiliensis, Garcinia cambogia); polyunsaturated diacylglycerides; Green tea extracts (caffeine, epigallocatechin gallate ... On the other hand, the composition comprises biogenic polyamines for the conversion of metabolically diseased into healthy adipocytes, in particular putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine and / or cadaverine.
Durch Verabreichung von (-)-Hydroxyzitronensäure (HCA), die im Folgenden stellvertretend für die o.g. Wirkstoffe und Wirkstoff-Komplexe zur Stimulierung des Fettabbaus und zur Hemmung des Aufbaus von Fettdepots in den Zellen genannt wird, welche als kompetitiver Inhibitor der Adenosintriphosphat-Citrat Fyase fungieren, wird die zelluläre Verfügbarkeit von Acetyl Coenzym A für die Fettsäure- und Cholesterinbiosynthese reduziert. Neben der Unterdrückung der de novo Fettsäurebiosynthese wird durch HCA Gabe auch die beta-Oxidation (Fipolyse) stimuliert und die Nahrungsaufnahme reduziert. By administering (-) - hydroxycitric acid (HCA), which in the following is representative of the above Active ingredients and active ingredient complexes to stimulate fat breakdown and to inhibit the build-up of fat deposits in the cells, which act as competitive inhibitors of the adenosine triphosphate citrate phase, reduce the cellular availability of acetyl coenzyme A for fatty acid and cholesterol biosynthesis. In addition to suppressing de novo fatty acid biosynthesis, administration of HCA also stimulates beta-oxidation (fipolysis) and reduces food intake.
Allerdings würde es, wenn man ausschließlich diese Wirkstoffe zum Fettabbau einsetzt, nach der Intervention wieder zu einer vermehrten Fetteinlagerung in den Adipozyten kommen (Yo-Yo Effekt), da sich nach Absetzen des Wirkstoffes HCA zwar das Fett in den Fettzellen reduziert hat, diese aufgrund ihrer metabolischen Dysfunktion erleichtert Fett aufzunehmen wieder kurzfristig Fett speichern werden. Durch die vermehrte Einlagerung von Fett haben vormals gesunde Fettzellen Fettdepots aufgebaut, welche dazu führen, dass die Aktivität der Enzyme der Fipogenese gesteigert wurde und auch nach Intervention durch HCA sich zwar die eingelagerten Fette abgebaut haben, aber die Aktivität der Enzyme der Fipogenese gesteigert bleiben. Die Struktur der bereits aufgrund der vorherigen übermäßigen Fettaufnahme nachteilig veränderten
metabolischen Funktion der Fettzellen bleibt in den„fettentleerten“ Zellen bestehen der unter Punkt 1 beschriebene Effekt herrscht auch nach Einnahme der Wirkstoffe vor. Somit tritt der oben unter Punkt 1 beschrieben Yo-Yo Effekt wieder ein. Daher kommt es nach Beendigung der Intervention ausschließlich mit HCA u.a. unter normaler Fettzufuhr zu einer erleichterten Steigerung der Fettablagerung in den metabolisch veränderten Adipozyten. However, if you only use these active ingredients for fat loss, there would be increased fat storage in the adipocytes again after the intervention (yo-yo effect), because after discontinuing the active ingredient HCA the fat in the fat cells has been reduced, due to this Their metabolic dysfunction makes it easier to absorb fat again in the short term to store fat. Due to the increased storage of fat, previously healthy fat cells have built up fat deposits, which lead to the activity of the enzymes of fipogenesis being increased and even after the intervention by HCA the stored fats have broken down, but the activity of the enzymes of fipogenesis remains increased. The structure of the already adversely changed due to the previous excessive fat intake The metabolic function of the fat cells remains in the "fat-depleted" cells. The effect described under point 1 also prevails after taking the active ingredients. Thus, the yo-yo effect described above under point 1 occurs again. Therefore, after the end of the intervention exclusively with HCA, among other things with normal fat intake, there is a facilitated increase in the fat deposition in the metabolically changed adipocytes.
Das erfindungsgemäße Nahrungsergänzungsmittel enthält jedoch darüber hinaus biogene Polyamine (z.B. Spermidin, das im Folgenden für diese Wirkstoffgruppe stellvertretend genannt wird) zur Umwandlung von metabolisch kranken in gesunde Adipozyten. Durch diese Wirkstoffe werden neue metabolisch gesunde Zellen, welche diese gesteigerte Bereitschaft zur Einlagerung von Fetten aufgrund der hohen Enzymaktivität nicht aufweisen, gebildet (Adipogenese). Die bereits metabolisch kranken Zellen werden durch die Verabreichung von Spermidin und die dadurch ausgelöste Autophagie in metabolisch gesunde Zellen umgewandelt. However, the food supplement according to the invention also contains biogenic polyamines (e.g. spermidine, which is mentioned below as representative of this group of active substances) for converting metabolically diseased into healthy adipocytes. These active ingredients create new metabolically healthy cells that do not show this increased willingness to store fats due to the high enzyme activity (adipogenesis). The cells that are already metabolically diseased are converted into metabolically healthy cells by the administration of spermidine and the resulting autophagy.
Durch zusätzliche Verabreichung des Wirkstoffes Spermidin werden neue metabolisch gesunde Zellen, welche diese gesteigerte Bereitschaft zur Einlagerung von Fetten aufgrund der hohen Enzymaktivität nicht aufweisen, gebildet (Adipogenese). Spermidin bewirkt eine Förderung des Zellwachstums und der Zelldifferenzierung im Zuge der Adipogenese. Zusätzlich stimuliert Spermidin die Autophagie der Zellen und baut dadurch bestehende alte Zellstrukturen und Proteine ab, die durch neue funktionale Bestandteile ersetzt werden. Die bereits metabolisch kranken Zellen werden durch die Verabreichung von Spermidin und die dadurch ausgelöste Autophagie in metabolisch gesunde Zellen umgewandelt. Through the additional administration of the active ingredient spermidine, new metabolically healthy cells are formed which do not show this increased willingness to store fats due to the high enzyme activity (adipogenesis). Spermidine promotes cell growth and differentiation in the course of adipogenesis. In addition, spermidine stimulates the autophagy of the cells and thereby breaks down existing old cell structures and proteins, which are replaced by new functional components. The cells that are already metabolically diseased are converted into metabolically healthy cells by the administration of spermidine and the resulting autophagy.
Das im erfindungsgemäßen Nahrungsergänzungsmittel enthaltene Spermidin (o.a. der Wirkstoffe dieser Gruppe) hat darüber hinaus die Eigenschaft, die Ausschüttung von entzündungshemmenden Botenstoffen zu induzieren, indem neue, metabolisch gesunde Adipozyten gebildet werden, welche antiinflammatorische Cytokine freisetzen, die u.a. den Glukosestoffwechsel regulieren und somit ebenfalls ein effektives Gewichtsmanagement fördern. The spermidine contained in the food supplement according to the invention (or the active ingredients of this group) also has the property of inducing the release of anti-inflammatory messenger substances by forming new, metabolically healthy adipocytes, which release anti-inflammatory cytokines which, among other things, regulate the glucose metabolism and thus also promote effective weight management.
Im Ergebnis ist die Verabreichung einer Kombination aus Wirkstoffen, die einerseits metabolisch dysfunktionale Fettzellen in metabolisch gesunde Fettzellen umwandeln und andererseits dieThe result is the administration of a combination of active ingredients, which on the one hand convert metabolically dysfunctional fat cells into metabolically healthy fat cells and on the other hand the
Fettmobilisierung forciert, ein neuartiger Ansatz zum nachhaltigen Gewichtsmanagement. DieForced fat mobilization, a novel approach to sustainable weight management. The
Kombination von HCA und Spermidin bewirkt somit nicht nur eine einfache Gewichtsreduktion, sondern fördert auch die nachhaltige metabolische Gesundheit, indem es die Umwandlung vonCombination of HCA and Spermidine thus not only causes an easy weight loss, but also promotes sustainable metabolic health by promoting the conversion of
Fettzellen mit gestörtem Stoffwechsel in metabolisch gesunde Fettzellen durch Stimulierung der
Adipogenese und Autophagie bei gleichzeitiger Mobilisierung bestehender Fettreserven und Hemmung der Lipogenese forciert. Fat cells with impaired metabolism are converted into metabolically healthy fat cells by stimulating the Adipogenesis and autophagy with simultaneous mobilization of existing fat reserves and inhibition of lipogenesis accelerated.
Während mit bekannten Wirkstoffzusammensetzungen zur Forcierung des Abbaus der Triglyzeride im Körper nur bedingt ein langanhaltender Fettabbau erreicht wird, kann mit Hilfe des erfindungsgemäßen Nahrungsergänzungsmittels ein nachhaltiges Gewichtsmanagement bzw. eine nachhaltige Gewichtsreduktion durch Fettabbau im Körper erreicht werden. While long-lasting fat breakdown is only achieved to a limited extent with known active ingredient compositions to force the breakdown of triglycerides in the body, sustainable weight management or sustainable weight reduction through fat breakdown can be achieved with the aid of the food supplement according to the invention.
Außerdem wurde bei Gabe der erfindungsgemäßen Wirkstoffzusammensetzung neben der dauerhaften Gewichtsreduktion ein Anti-Aging-Effekt erkannt, der auf die Inhaltsstoffe der Basisrezeptur bzw. deren Kombination zurückzuführen ist. In addition, when the active ingredient composition according to the invention was administered, in addition to the permanent weight reduction, an anti-aging effect was recognized which can be attributed to the ingredients of the basic formulation or their combination.
Als für die Basisrezeptur des erfindungsgemäßen Nahrungsergänzungsmittels besonders geeignet hat sich eine Kombination aus (-)-Hydroxyzitronensäure enthaltenen Garcinia Extrakt und Spermidin erwiesen. A combination of (-) - hydroxycitric acid containing Garcinia extract and spermidine has proven to be particularly suitable for the basic formulation of the food supplement according to the invention.
Neben der Umwandlung von dysfunktionalen Fettzellen in metabolisch gesunde Zellen ist eine Mobilisierung von bestehenden Triglyzeriden in den Fettzellen essentiell. (-)HCA, vor allem als Salz von zweiwertigen Kationen, stimuliert den Fettabbau (beta-Oxidation) und verhindert die Lipogenese, indem es die Verfügbarkeit von Acetyl-CoA, als wichtigen Baustein für die Fettsäurebiosynthese, begrenzt. Dadurch können selbst bei kohlenhydratreicher Ernährung die Kohlenhydrate nicht in Fett umgewandelt und gespeichert werden. In addition to the conversion of dysfunctional fat cells into metabolically healthy cells, mobilization of existing triglycerides in the fat cells is essential. (-) HCA, especially as a salt of divalent cations, stimulates fat breakdown (beta-oxidation) and prevents lipogenesis by limiting the availability of acetyl-CoA, an important building block for fatty acid biosynthesis. As a result, even with a high-carbohydrate diet, the carbohydrates cannot be converted into fat and stored.
Die Basisrezeptur mit den angegebenen Mindestmengen an Inhaltsstoffen sorgt für die erfindungsgemäßen Wirkungen. Die im Folgenden genannten Zusatzstoffe werden optional hinzugefügt, um spezielle Zielsetzungen zu erfüllen bzw. Zusatzwirkungen bzw. Verstärkungen der erfindungsgemäßen Wirkungen zu erzielen. The basic formulation with the specified minimum amounts of ingredients ensures the effects according to the invention. The additives mentioned below are optionally added in order to meet specific objectives or to achieve additional effects or reinforcements of the effects according to the invention.
Insbesondere umfasst das Nahrungsergänzungsmittel : 0,5-80 Gew.-%, insbesondere 30-70 Gew - %, des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Derivaten der Zitronensäure, insbesondere zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers, Extrakten aus Garcinia Arten, mehrfach ungesättigten Diacylglyzeriden, und Grünteeextrakt; und In particular, the food supplement comprises: 0.5-80% by weight, in particular 30-70% by weight, of the one or more ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of (-) - hydroxycitric acid Isomers, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract; and
0,001-20 Gew.-%, insbesondere 0,002-0,060 Gew.-%, des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Putrescin, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und Cadaverin.
Vorzugsweise enthält das Nahrungsergänzungsmittel zwischen einschließlich 0,25 und 40 g, insbesondere zwischen einschließlich 0,15 und 35 g, des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Derivaten der Zitronensäure, insbesondere zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers, Extrakten aus Garcinia Arten, mehrfach ungesättigten Diacylglyzeriden, und Grünteeextrakt, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels; und/oder 0.001-20% by weight, in particular 0.002-0.060% by weight, of the one or more ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine, and cadaverine. The dietary supplement preferably contains between 0.25 and 40 g, in particular between 0.15 and 35 g, of the one or more ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of (-) - hydroxycitric acid Isomers, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract, based on a daily dose of the dietary supplement; and or
zwischen einschließlich 0,0005 und 2,5 g, insbesondere zwischen 0,0007 und 0,03 g, des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Putrescin, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und Cadaverin, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels. between 0.0005 and 2.5 g, in particular between 0.0007 and 0.03 g, of the one or more ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine, and cadaverine, based on a Daily dose of the dietary supplement.
Die Gewichtsangaben beziehen sich auf eine einzunehmende empfohlene Tagesdosis des Nahrungsergänzungsmittels. Eine Tagesdosis beträgt für die o.a. Gewichtsangaben in der Regel 50 g. Weitere mögliche Inhaltsstoffe ergeben sich aus der nachfolgenden Beschreibung, wobei die Mengenangaben, soweit sie als Gewichtsangaben angegeben sind, sich auf 100 g des Nahrungsergänzungsmittels beziehen, also ohne weiteres in Gew.-% umgerechnet werden können. Darüber hinaus kann das Nahrungsergänzungsmittel vorteilhafterweise 0-0,500 Gew.-% Piperin, insbesondere 0,150-0,350 Gew.-% Piperin enthalten. Piperin steigert die Bioverfügbarkeit der Wirkstoffe des erfindungsgemäßen Nahrungsergänzungsmittels und verstärkt somit die Wirkungen der Zusammensetzung. The weight information relates to a recommended daily dose of the dietary supplement to be taken. A daily dose for the above is Weight specifications usually 50 g. Further possible ingredients emerge from the following description, the quantitative data, insofar as they are given as weight data, relate to 100 g of the food supplement, that is to say can easily be converted into% by weight. In addition, the food supplement can advantageously contain 0-0.500% by weight piperine, in particular 0.150-0.350% by weight piperine. Piperine increases the bioavailability of the active ingredients of the food supplement according to the invention and thus enhances the effects of the composition.
Insbesondere kann das Nahrungsergänzungsmittel weiterhin bis maximal 10 g Fett, insbesondere 0 bis 10 Gew.-% gesättigte Fettsäuren, insbesondere 0 bis 10 Gew.-% Omega-3 Fettsäuren enthalten. Durch die Zugabe von Omega-3 Fettsäuren wird eine Steigerung der Feistung und der Gesundheit erreicht. In particular, the food supplement can furthermore contain up to a maximum of 10 g fat, in particular 0 to 10% by weight of saturated fatty acids, in particular 0 to 10% by weight of omega-3 fatty acids. By adding omega-3 fatty acids, an increase in moisture and health is achieved.
Optional kann das Nahrungsergänzungsmittel Kohlenhydrate, jedoch maximal 33 Gew.-% Kohlenhydrate in Form von Zucker enthalten. Kohlenhydrate werden dann optional hinzugegeben, wenn eine lang anhaltende Wirkung bei Ausdauertraining und Einnahme des Nahrungsergänzungsmittels vor der sportlichen Betätigung erzielt werden soll. Die Zugabe eines Anteils von Zucker (z.B. Traubenzucker) sorgt für eine sofortige und kurzfristig wirksame Energiezufuhr beim Ausdauertraining.
Darüber hinaus kann das Nahrungsergänzungsmittel maximal 93 Gew.-% Eiweiß enthalten. Die Zugabe von Eiweiß fördert den Muskelaufbau bei Krafttraining. Statt Eiweiß können dem Nahrungsergänzungsmittel auch Aminosäuren zugegeben werden. The food supplement can optionally contain carbohydrates, but a maximum of 33% by weight of carbohydrates in the form of sugar. Carbohydrates are then optionally added if a long-lasting effect is to be achieved during endurance training and taking the food supplement before exercise. The addition of a proportion of sugar (e.g. grape sugar) ensures an immediate and short-term effective supply of energy during endurance training. In addition, the dietary supplement can contain a maximum of 93% by weight of protein. The addition of protein promotes muscle building during strength training. Instead of protein, amino acids can also be added to the dietary supplement.
Das Nahrungsergänzungsmittel kann maximal 3,3 Gew.-% rote Beete enthalten. Mittels dieses Zusatzes wird eine Steigerung der Ausdauer und Gesundheit (Blutdrucksenkend) erreicht. The dietary supplement can contain a maximum of 3.3% by weight beetroot. By means of this addition, an increase in endurance and health (lowering blood pressure) is achieved.
Insbesondere kann das Nahrungsergänzungsmittel maximal 266,5 mg Vitamin C, bezogen eine Tagesdosis des Nahrungsergänzungsmittels enthalten. Vitamin C sorgt für eine weitere Steigerung der Ausdauer. Bevorzugt sind 100-133 mg Vitamin C enthalten. In particular, the food supplement can contain a maximum of 266.5 mg of vitamin C, based on a daily dose of the food supplement. Vitamin C ensures a further increase in endurance. 100-133 mg of vitamin C are preferred.
Das Nahrungsergänzungsmittel kann bis zu maximal 1,3 g Koffein, insbesondere als Extrakt aus grünem Tee, bezogen auf 100 g des Nahrungsergänzungsmittels, enthalten. Die Einnahme von Koffein regt den Fettabbau an und führt zudem zu einer Steigerung der Motivation. The food supplement can contain up to a maximum of 1.3 g of caffeine, in particular as an extract from green tea, based on 100 g of the food supplement. The consumption of caffeine stimulates fat loss and also leads to an increase in motivation.
Das Nahrungsergänzungsmittel kann bis zu maximal 5 g Resveratrol und/oder Traubenkernextrakt, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthalten. Dieser Wirkstoff kann zugegeben werden, um den Anti-Age-Effekt zu verstärken. Der Wirkstoff wirkt als Antioxidans. Bevorzugt werden 1,75-3,75 g Resveratrol und/oder Traubenkernextrakt zugesetzt. The food supplement can contain a maximum of 5 g resveratrol and / or grape seed extract, based on a daily dose of the food supplement. This active ingredient can be added to increase the anti-aging effect. The active ingredient acts as an antioxidant. Preferably 1.75-3.75 g resveratrol and / or grape seed extract are added.
Vorzugsweise kann das Nahrungsergänzungsmittel bis zu maximal 5 g L-Citrullin, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels enthalten. L-Citrullin führt einerseits zu einer Leistungssteigerung, und verringert andererseits das Risiko bzw. die Auswirkungen eines Muskelkaters (Senkung des Plasmalaktatspiegels). Bevorzugt enthält das Nahrungsergänzungsmittel 1,75-3,75 g L-Citrullin. The food supplement can preferably contain up to a maximum of 5 g of L-citrulline, based on a daily dose of the food supplement. L-citrulline leads on the one hand to an increase in performance and on the other hand reduces the risk or the effects of sore muscles (lowering of the plasma lactate level). The dietary supplement preferably contains 1.75-3.75 g of L-citrulline.
Das Nahrungsergänzungsmittel kann bis zu maximal 1,65 g L-Tryptophan und/oder L-Tyrosin, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthalten. Diese Stoffe fördern die Bildung von Glückshormonen. Ihre Einnahme führt somit zu einer Steigerung der Motivation, z.B. sich körperlich zu betätigen und fördert damit die Effekte der Basisrezeptur. Bevorzugt können 0,5-1 g L-Tryptophan und/oder L-Tyrosin enthalten sein. The dietary supplement can contain up to a maximum of 1.65 g L-tryptophan and / or L-tyrosine, based on a daily dose of the dietary supplement. These substances promote the formation of happiness hormones. Taking them leads to an increase in motivation, e.g. to be physically active and thus promotes the effects of the basic recipe. It can preferably contain 0.5-1 g of L-tryptophan and / or L-tyrosine.
Das Nahrungsergänzungsmittel kann bis zu maximal 2,3 mg Vitamin B6, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthalten. Auch Vitamin B6 fördert die Bildung von Glückshormonen und führt damit zu einer Steigerung der Motivation.
Das Nahrungsergänzungsmittel kann bis zu maximal 1 g Salz, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthalten. The dietary supplement can contain up to a maximum of 2.3 mg vitamin B6, based on a daily dose of the dietary supplement. Vitamin B6 also promotes the formation of happiness hormones and thus increases motivation. The food supplement can contain up to a maximum of 1 g of salt, based on a daily dose of the food supplement.
Das Nahrungsergänzungsmittel kann zusätzlich Chrom (z.B. 0,01 - 0,1 mg) und/oder Cholin (z.B. 50 - 1000 mg), bezogen auf eine Tagesdosis, enthalten. The food supplement can also contain chromium (e.g. 0.01-0.1 mg) and / or choline (e.g. 50-1000 mg), based on a daily dose.
Das Nahrungsergänzungsmittel kann prinzipiell in allen möglichen Formen bereitgestellt werde, z.B. als Kapsel, als Lösung bzw. Suspension der Inhaltsstoffe, als in Wasser lösbares Pulver, oder aber als fertiges Getränk (Fitnessgetränk). Im Fall eines Fitnessgetränks werden die für das erfindungsgemäße Nahrungsergänzungsmittel angegebenen Mengen in Gewichtsanteile oder in absoluten Gewichtsangaben, die sich auf das fertige bzw. bestimmungsgemäß zuzubereitende Getränk beziehen, angegeben. Als Basis für das Getränk wird ein Hilfs- oder Füllstoffe, z.B. Wasser, verwendet werden, in dem die anderen Inhaltsstoffe bzw. erfindungsgemäßen Wirkstoffe gelöst sind. Es ist jedoch beispielsweise auch eine Suspension aus Wasser und Aminosäuren als Basis für ein Getränk denkbar, in der die anderen Inhaltsstoffe gelöst bzw. in die die erfindungsgemäßen Wirkstoffe eingebracht sind. The food supplement can in principle be provided in all possible forms, e.g. as a capsule, as a solution or suspension of the ingredients, as a powder that can be dissolved in water, or as a finished drink (fitness drink). In the case of a fitness drink, the amounts given for the food supplement according to the invention are given in parts by weight or in absolute weight figures which relate to the finished drink or drink to be prepared as intended. As a basis for the drink, an auxiliary or filler, e.g. Water, in which the other ingredients or active ingredients according to the invention are dissolved. However, a suspension of water and amino acids, for example, is also conceivable as the basis for a drink, in which the other ingredients are dissolved or into which the active ingredients according to the invention are incorporated.
Weitere Hilfs- oder Füllstoffe, z.B. für Kapseln, sind Wasser, Hydroxypropylmethylcellulose, Aminosäuren und/oder Speisefettsäuren. Die Tagesdosis an notwendigen oder optionalen Inhaltsstoffen kann beliebig mit Hilfs- oder Füllstoffen versetzt werden, um das Nahrungsergänzungsmittel in der gewünschten Darreichungsform bereitzustellen. Im Übrigen besteht im Rahmen der Erfindung die Möglichkeit, Protein-, Kohlenhydrat- und Fettzusammensetzung des Nahrungsergänzungsmittels in Abhängigkeit von Somatotyp, Zielsetzung (z.B. Gewichtsabnahme, sportliche Leistungssteigerung, etc.) und/oder physiologischen Paramatern (z.B. Blutdruck) zu bestimmen. Further auxiliaries or fillers, e.g. for capsules, are water, hydroxypropylmethylcellulose, amino acids and / or fatty acids. The daily dose of necessary or optional ingredients can be mixed with any auxiliaries or fillers in order to provide the food supplement in the desired dosage form. In addition, within the scope of the invention there is the possibility of determining the protein, carbohydrate and fat composition of the food supplement as a function of the somatotype, objective (e.g. weight loss, sporting performance increase, etc.) and / or physiological parameters (e.g. blood pressure).
Außerdem besteht die Möglichkeit, sämtliche Inhaltsstoffe aus Pflanzen zu gewinnen und/oder synthetisch herzustellen, sodass ein veganes Fitnessgetränk hergestellt werden kann. It is also possible to obtain all of the ingredients from plants and / or to produce them synthetically, so that a vegan fitness drink can be made.
DETAILLIERTE BESCHREIBUNG BEVORZUGTER AU SFUHRUN GSBEISPIELE DETAILED DESCRIPTION OF PREFERRED AU SFUHRUN G EXAMPLES
Die folgenden Nahrungsergänzungsmittel in Form eines Fitness-Getränks erfüllen die Zwecke Gewichtsmanagement. Je nach Somatotyp und Zielsetzung kann die Rezeptur durch Einstellung der genauen Mengen an Wirkstoffen und optionalen Zusatzstoffen angepasst werden. Die
folgenden Beispiele entsprechen Rezepturen, die bei bestimmten (zusätzlichen) Zielsetzungen effektiv wirksam sind. The following diet supplements in the form of a fitness drink are for weight management purposes. Depending on the somatotype and the objective, the recipe can be adapted by setting the exact amounts of active ingredients and optional additives. The The following examples correspond to formulations that are effective for certain (additional) objectives.
Beispiel 1 : Example 1 :
Zielsetzung: Steigerung der Ausdauer Objective: increase endurance
2-4 g zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers 2-4 g of di- or trivalent salts of the (-) - hydroxycitric acid isomer
0,0025-1 g Spermidin 0.0025-1 g spermidine
50-150 mg Piperin 50-150 mg piperine
2.5-7, 5 g Omega-3 Fettsäuren 2.5-7.5 g of omega-3 fatty acids
20-50 g Kohlenhydrate 20-50 g of carbohydrates
20-50 g Proteine 20-50 g protein
1.5-3, 3 g rote Beete 1.5-3.3 g beetroot
100-266 mg Vitamin C 100-266 mg of vitamin C.
2.5-4, 5 g L-Citrullin 2.5-4.5 g L-citrulline
Rest: Hilfsstoff, z.B. Wasser Remainder: auxiliary, e.g. water
Beispiel 2: Example 2:
Zielsetzung: Steigerung der Ausdauer Objective: increase endurance
3 g zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers 3 g of di- or trivalent salts of the (-) - hydroxycitric acid isomer
0,0015-0,002 g Spermidin 0.0015-0.002 g spermidine
100 mg Piperin 100 mg piperine
5 g Omega-3 Fettsäuren 5 g of omega-3 fatty acids
35 g Kohlenhydrate 35 g of carbohydrates
35 g Proteine 35 g protein
2,5 g rote Beete
200 mg Vitamin C 2.5 g beetroot 200 mg of vitamin C.
5 g L-Citrullin 5 g L-citrulline
Rest: Hilfsstoff, z.B. Wasser Remainder: auxiliary, e.g. water
Beispiel 3: Example 3:
Zielsetzung: Gewichtsreduktion, Erhöhter Anti-Aging-Effekt Objective: Weight reduction, increased anti-aging effect
7-10 g zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers 7-10 g of di- or trivalent salts of the (-) - hydroxycitric acid isomer
0,002-3,0 g Spermidin 0.002-3.0 g spermidine
250-500 mg Piperin 250-500 mg piperine
20-50 g Eiweiß/Aminosäuren 20-50 g protein / amino acids
200-266,6 mg Vitamin C 200-266.6 mg of vitamin C.
0,325-1,3 g Koffein 0.325-1.3 g of caffeine
7,5-10 g Resveratrol 7.5-10 g resveratrol
Rest: Hilfsstoff, z.B. Wasser Remainder: auxiliary, e.g. water
Beispiel 4: Example 4:
Zielsetzung: Gewichtsreduktion, Erhöhter Anti-Aging-Effekt Objective: Weight reduction, increased anti-aging effect
8 g zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers 8 g of di- or trivalent salts of the (-) - hydroxycitric acid isomer
0,001-0,5 g Spermidin 0.001-0.5 g spermidine
400 mg Piperin 400 mg of piperine
35 g Ei weiß/ Aminosäuren 35 g egg white / amino acids
266,6 mg Vitamin C 266.6 mg of vitamin C.
0,7 g Koffein 0.7 g of caffeine
8 g Resveratrol 8 g resveratrol
Rest: Hilfsstoff, z.B. Wasser
Beispiel 5: Remainder: auxiliary material, e.g. water Example 5:
Zielsetzung: Steigerung der Motivation Objective: increase motivation
2-5 g zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers 2-5 g of di- or trivalent salts of the (-) - hydroxycitric acid isomer
0,001-0,025 g Spermidin 0.001-0.025 g spermidine
300-500 mg Piperin 300-500 mg piperine
10-50 mg Vitamin C 10-50 mg of vitamin C.
1,0- 1,3 g Koffein 1.0-1.3 g of caffeine
2-3,3 g L-Tryptophan und/oder L-Tyrosin 2-3.3 g of L-tryptophan and / or L-tyrosine
3-4,6 mg Vitamin B6 3-4.6 mg of vitamin B6
Rest: Hilfsstoff, z.B. Wasser Remainder: auxiliary, e.g. water
Beispiel 6: Example 6:
Zielsetzung: Steigerung der Motivation Objective: increase motivation
3 g zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers 0,001 g Spermidin 3 g of di- or trivalent salts of the (-) - hydroxycitric acid isomer 0.001 g of spermidine
400 mg Piperin 400 mg of piperine
50 mg Vitamin C 50 mg of vitamin C.
1 g Koffein 1 g of caffeine
1,5 g L-Tryptophan 1.5 grams of L-tryptophan
1,5 g L-Tyrosin 1.5 g L-tyrosine
4 mg Vitamin B6 4 mg of vitamin B6
Rest: Hilfsstoff, z.B. Wasser
Die Angaben beziehen sich auf 100 mg des Nahrungsergänzungsmittels In den vorhergehenden Beispielen kann als Tagesdosis beispielsweise, je nach Wunsch und physiologischer Remainder: auxiliary material, e.g. water The data relate to 100 mg of the food supplement. In the preceding examples, the daily dose can be, for example, depending on the request and physiological
Beschaffenheit des Anwenders, 30g - 60 g empfohlen werden. Condition of the user, 30g - 60 g are recommended.
Das folgenden Nahrungsergänzungsmittel in Form einer Kapsel erfüllt die Zwecke Gewichtsmanagement. Je nach Somatotyp und Zielsetzung kann die Rezeptur durch Einstellung der genauen Mengen an Wirkstoffen und optionalen Zusatzstoffen angepasst werden. The following dietary supplement in capsule form serves weight management purposes. Depending on the somatotype and the objective, the recipe can be adapted by setting the exact amounts of active ingredients and optional additives.
Beispiel 7: Example 7:
Dieses Beispiel betrifft eine Darreichungsform als Kapsel mit 1 g Gewicht. Die Mengen sind im Folgenden für zwei Kapseln a 1 g angegeben: This example relates to a dosage form as a capsule weighing 1 g. The quantities are given below for two 1 g capsules:
Eine Tagesdosis entspricht in diesem Fall zwei (2) Kapseln.
In this case, a daily dose corresponds to two (2) capsules.
Claims
1. Nahrungsergänzungsmittel, umfassend: 1. Food supplements, comprising:
einen oder mehrere der Inhaltsstoffe aus einer Gruppe von Derivaten der Zitronensäure, insbesondere zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers, Extrakten aus Garcinia Arten, mehrfach ungesättigten Diacylglyzeriden, und Grünteeextrakt; und one or more of the ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of the (-) - hydroxycitric acid isomer, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract; and
einen oder mehrere der Inhaltsstoffe aus einer Gruppe von Putrescin, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und Cadaverin. one or more of the ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermin, diacetylspermin, and cadaverine.
2. Nahrungsergänzungsmittel nach Anspruch 1, umfassend: 2. Food supplement according to claim 1, comprising:
0,5-80 Gew.-% des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Derivaten der Zitronensäure, insbesondere zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers, Extrakten aus Garcinia Arten, mehrfach ungesättigten Diacylglyzeriden, und Grünteeextrakt; und 0,001-20 Gew.-% des einen oder der mehreren Inhalts Stoffe aus einer Gruppe von Putrescin, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und Cadaverin. 0.5-80% by weight of the one or more ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of the (-) - hydroxycitric acid isomer, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract; and 0.001-20% by weight of the one or more ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine, and cadaverine.
3. Nahrungsergänzungsmittel nach Anspruch 1 oder 2, dudurch gekennzeichnet, dass das Nahrungsergänzungsmittel zwischen einschließlich 0,25 und 40 g des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Derivaten der Zitronensäure, insbesondere zwei- oder dreiwertige Salze des (-)-Hydroxyzitronensäure-Isomers, Extrakten aus Garcinia Arten, mehrfach ungesättigten Diacylglyzeriden, und Grünteeextrakt, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels; und/oder 3. Food supplement according to claim 1 or 2, characterized in that the food supplement includes between 0.25 and 40 g of the one or more ingredients from a group of derivatives of citric acid, in particular di- or trivalent salts of (-) - hydroxycitric acid Isomers, extracts from Garcinia species, polyunsaturated diacylglycerides, and green tea extract, based on a daily dose of the dietary supplement; and or
zwischen einschließlich 0,0005 und 2,5 g des einen oder der mehreren Inhaltsstoffe aus einer Gruppe von Putrescin, Spermidin, Acetylspermidin, Spermin, Acetylspermin, Diacetylspermin, und Cadaverin, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthält. contains between 0.0005 and 2.5 g of the one or more ingredients from a group of putrescine, spermidine, acetylspermidine, spermine, acetylspermine, diacetylspermine, and cadaverine, based on a daily dose of the dietary supplement.
4. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch 4. Food supplement according to one of the preceding claims, characterized
gekennzeichnet, dass es weiterhin 0,0167-0,500 Gew.-% Piperin enthalten kann.
characterized in that it can further contain 0.0167-0.500% by weight of piperine.
5. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es weiterhin bis maximal 10 Gew-% Fett, insbesondere 0 bis 10 Gew.-% gesättigte Fettsäuren, insbesondere 0 bis 10 Gew.-% Omega- 3 Fettsäuren enthält. 5. Food supplement according to one of the preceding claims, characterized in that it furthermore contains up to a maximum of 10% by weight of fat, in particular 0 to 10% by weight of saturated fatty acids, in particular 0 to 10% by weight of omega-3 fatty acids.
6. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es weiterhin Kohlenhydrate, jedoch maximal 93 Gew.-% Kohlenhydrate in Form von Maltodextrinen und Dextrose enthält. 6. Food supplement according to one of the preceding claims, characterized in that it also contains carbohydrates, but a maximum of 93% by weight of carbohydrates in the form of maltodextrins and dextrose.
7. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 93 Gew.-% Eiweiß enthält. 7. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 93 wt .-% protein.
8. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 3,3 Gew.-% rote Beete enthält. 8. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 3.3 wt .-% beetroot.
9. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 266,6 mg Vitamin C, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthält. 9. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 266.6 mg of vitamin C, based on a daily dose of the food supplement.
10. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 1,3 g Koffein, insbesondere als Extrakt aus grünem Tee, bezogen auf 100 g des Nahrungsergänzungsmittels, enthält. 10. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 1.3 g of caffeine, in particular as an extract from green tea, based on 100 g of the food supplement.
11. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 5 g Resveratrol und/oder Traubenkernextrakt, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthält. 11. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 5 g resveratrol and / or grape seed extract, based on a daily dose of the food supplement.
12. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 5 g L-Citrullin, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthält.
12. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 5 g of L-citrulline, based on a daily dose of the food supplement.
13. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 1,65 g L-Tryptophan und/oder L-Tyrosin, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthält. 13. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 1.65 g of L-tryptophan and / or L-tyrosine, based on a daily dose of the food supplement.
14. Nahrungsergänzungsmittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es maximal 2,3 mg Vitamin B6, bezogen auf eine Tagesdosis des Nahrungsergänzungsmittels, enthält.
14. Food supplement according to one of the preceding claims, characterized in that it contains a maximum of 2.3 mg of vitamin B6, based on a daily dose of the food supplement.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112020001186.0T DE112020001186A5 (en) | 2019-03-11 | 2020-03-10 | dietary supplements |
CH0702542021A CH717329B1 (en) | 2019-03-11 | 2020-03-10 | Dietary supplements |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA90/2019 | 2019-03-11 | ||
AT902019 | 2019-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020182831A1 true WO2020182831A1 (en) | 2020-09-17 |
Family
ID=69810833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/056386 WO2020182831A1 (en) | 2019-03-11 | 2020-03-10 | Food supplement |
Country Status (3)
Country | Link |
---|---|
CH (1) | CH717329B1 (en) |
DE (1) | DE112020001186A5 (en) |
WO (1) | WO2020182831A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344287A (en) * | 2021-12-24 | 2022-04-15 | 苏州麦轮生物科技有限公司 | Spermidine-containing nutritional ingredient and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003254759A1 (en) * | 2002-04-19 | 2005-05-05 | Ravi Shrivastava | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
KR20090105202A (en) * | 2008-04-01 | 2009-10-07 | 주식회사 두향원 | Fermented soybeans for body fat control and the method of thereof |
US20100173025A1 (en) * | 2007-09-04 | 2010-07-08 | Nisshin Pharma Inc. | Fat absorption inhibitory composition |
-
2020
- 2020-03-10 CH CH0702542021A patent/CH717329B1/en unknown
- 2020-03-10 DE DE112020001186.0T patent/DE112020001186A5/en active Pending
- 2020-03-10 WO PCT/EP2020/056386 patent/WO2020182831A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003254759A1 (en) * | 2002-04-19 | 2005-05-05 | Ravi Shrivastava | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
US20100173025A1 (en) * | 2007-09-04 | 2010-07-08 | Nisshin Pharma Inc. | Fat absorption inhibitory composition |
KR20090105202A (en) * | 2008-04-01 | 2009-10-07 | 주식회사 두향원 | Fermented soybeans for body fat control and the method of thereof |
Non-Patent Citations (8)
Title |
---|
ANONYMOUS: "Beetroot juice - a potent weight loss drink that can help lower blood pressure, boost immunity | Health Tips and News", 29 October 2018 (2018-10-29), pages 1 - 3, XP055697079, Retrieved from the Internet <URL:https://www.timesnownews.com/health/article/how-to-lose-weight-fast-include-beetroot-juice-in-your-weight-loss-diet-to-burn-belly-fat-effectively/304888> [retrieved on 20200519] * |
CLAUDIA WEISS: "Biogene Amine", ERNÄHRUNGSUMSCHAU, 1 March 2009 (2009-03-01), pages 172 - 179, XP055691706, Retrieved from the Internet <URL:https://www.ernaehrungs-umschau.de/fileadmin/Ernaehrungs-Umschau/pdfs/pfd_2009/03_09/EU03_172_179.qxd.pdf> [retrieved on 20200505] * |
DATABASE GNPD [online] MINTEL; 7 December 2015 (2015-12-07), ANONYMOUS: "Liquid Vital Supplement Concentrate", XP055692060, retrieved from www.gnpd.com Database accession no. 3594023 * |
FRANK MADEO ET AL: "Spermidine in health and disease", SCIENCE, vol. 359, no. 6374, 26 January 2018 (2018-01-26), US, pages eaan2788, XP055691981, ISSN: 0036-8075, DOI: 10.1126/science.aan2788 * |
LUISA GILARDINI ET AL: "Effects of Greenselect Phytosome on weight maintenance after weight loss in obese women: a randomized placebo-controlled study", BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 16, no. 1, 22 July 2016 (2016-07-22), XP055696979, DOI: 10.1186/s12906-016-1214-x * |
NELLY C. MUÑOZ-ESPARZA ET AL: "Polyamines in Food", FRONTIERS IN NUTRITION, vol. 6, 11 July 2019 (2019-07-11), XP055696803, DOI: 10.3389/fnut.2019.00108 * |
REZA TABRIZI ET AL: "The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials", CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, vol. 60, no. 3, 13 November 2018 (2018-11-13), USA, pages 375 - 390, XP055696903, ISSN: 1040-8398, DOI: 10.1080/10408398.2018.1529654 * |
SHARPE P A ET AL: "Availability of Weight-Loss Supplements: Results of an Audit of Retail Outlets in a Southeastern City", JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, THE ASSOCIATION, CHICAGO, IL, US, vol. 106, no. 12, 1 December 2006 (2006-12-01), pages 2045 - 2051, XP027909487, ISSN: 0002-8223, [retrieved on 20061201] * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344287A (en) * | 2021-12-24 | 2022-04-15 | 苏州麦轮生物科技有限公司 | Spermidine-containing nutritional ingredient and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CH717329B1 (en) | 2024-07-15 |
DE112020001186A5 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018041684A1 (en) | Use of collagen hydrolysate for improving endurance performance and for stimulating lipocatabolism | |
EP0046167B1 (en) | Nutrient solution for complete extra-buccal feeding and for an enhanced production of energy, and manufacturing process | |
DE3785667T2 (en) | ADDITIONAL FOOD OR THERAPY FOR PERSONS WITH RISK OR TREATMENT FOR ARTERIOSCLEROTIC VASCULAR, CARDIOVASCULAR AND / OR THROMBOTIC DISEASES. | |
DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
DE102009016119A1 (en) | Nutritional supplement containing alpha-keto acids to support diabetes therapy | |
WO1993021912A1 (en) | Use of an emulsion containing omega-3 fatty acids to produce a medicament to be parenterally administered for treating inflammatory diseases | |
EP0756827A2 (en) | Composition for nutrition | |
EP2222292B1 (en) | Novel use of omega-3-fatty acid(s) | |
EP2129241A2 (en) | Food supplement containing alpha-keto acids | |
DE69832520T2 (en) | USE OF CONJUGATED LINOLEIC ACID FOR THE TREATMENT OF TYPE II DIABETES | |
DE102018104590A1 (en) | Nutraceutical or pharmaceutical composition | |
WO2020182831A1 (en) | Food supplement | |
AT513274B1 (en) | Dietary supplements | |
WO2005023271A1 (en) | Physiologically active composition based on phosphatidylserine | |
DE102017102873A1 (en) | Use of collagen hydrolyzate to improve endurance and stimulate fat loss | |
AT510810B1 (en) | COMBINATION PROCEDURE FOR IMPROVING FEMALE FERTILITY | |
EP2731454A1 (en) | Dietetic multi-component system | |
DE19830768A1 (en) | Creatine-containing comprises neurotransmitter and alpha-liponic acid useful for treating muscular dystrophy and for preventing obesity in muscular dystrophy sufferers | |
LU501504B1 (en) | POWDERED FOOD SUPPLEMENT FOR MAKING A BEVERAGE | |
DE10352822A1 (en) | Use of an additionally fermented cereal sludge for the prevention and / or treatment of elevated blood sugar levels | |
WO2003011309A2 (en) | Pharmaceutical composition for treating hypercholesterolaemia | |
AT413943B (en) | L-CARNITINE-CONTAINING, ORAL ADMINISTRATIVE COMPOSITION | |
WO2024208506A1 (en) | Oral active ingredient combination containing l-arginine, l-citrulline, selenite and water-soluble boron | |
WO2024023311A1 (en) | Orodispersible tablet, in particular for use as a food supplement | |
DE202023001978U1 (en) | Formulation comprising Coenzyme Q10 and creatine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20711116 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: R225 Ref document number: 112020001186 Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20711116 Country of ref document: EP Kind code of ref document: A1 |